X0306 4 2022-03-01 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001188919 LOVE TED W C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President and CEO Common Stock 2022-02-28 5 A 0 E 839 25.37 A 789616 D Common Stock 2022-03-01 4 M 0 9445 A 799061 D Common Stock 2022-03-01 4 F 0 4074 29.87 D 794987 D Common Stock 102000 I By Trust 1 Common Stock 102000 I By Trust 2 Common Stock 102000 I By Trust 3 Common Stock 2500 I By Daughter Common Stock 2500 I By Daughter Restricted Stock Units 2022-03-01 4 M 0 9445 0.00 D Common Stock 9445 56667 D Restricted Stock Units 2022-03-01 4 A 0 72877 0.00 A Common Stock 72877 72877 D Restricted Stock Units 2022-03-01 4 A 0 72877 0.00 A Common Stock 72877 72877 D Stock Option (Right to buy) 29.87 2022-03-01 4 A 0 118090 0.00 A 2032-02-28 Common Stock 118090 118090 D Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 9,445 shares of Common Stock underlying the Reporting Person's RSUs. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the RSUs vest in two installments, if at all, based on (i) the Issuer's total shareholder return percentile ranking relative to the companies in the NASDAQ Biotechnology Index for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date, and (ii) the percentage of patient share relative to a comparator group for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the stock option vest in 16 equal quarterly installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. /s/ Miguel Carrillo, Attorney-in-Fact 2022-03-03